Lancet: CGM helps basal insulin users
- The FreeDM2 trial, published in The Lancet Diabetes & Endocrinology in April 2026, showed real-time CGM beat finger-prick monitoring in adults with type 2 diabetes using basal insulin. (medicaldialogues.in) - In 303 UK participants, CGM cut HbA1c more at 16 weeks and added about 2.5 hours a day in the 70–180 mg/dL range. (abbott.mediaroom.com) - That matters because CGM access often lags for basal-insulin users, even though this group still struggles to hit glucose targets. (thelancet.com)
Continuous glucose monitoring just got a stronger case in type 2 diabetes — not for people on complex insulin regimens, but for a group that often gets left out. The new FreeDM2 trial looked at ad(medicaldialogues.in) coverage rules and clinical habits have often treated CGM as a tool mainly for type 1 diabetes or for people taking multiple daily insulin doses. (medicaldialogues.in) ### What exactly changed? The news is the publication of FreeDM2 in *The Lancet D(thelancet.com)out two-thirds assigned to real-time CGM and the rest to standard self-monitoring of blood glucose with finger-prick tests. Everyone had type 2 diabetes, was using basal insulin, and was also on newer glucose-lowering drugs like SGLT2 inhibitors or GLP-1–based therapies. (medicaldialogues.in) ### Why is basal insulin the interesting group? Basal insulin users sit in an aw(medicaldialogues.in)ity, dose timing, and dose adjustment — and many still miss HbA1c targets. That makes them a real test of whether better feedback alone can improve control. (thelancet.com) ### What did the trial show? The headline result is better glucose control with CGM. At 16 weeks, people using real-time CGM had a greater HbA1c reduction than the finger-prick group — about 0.6 p(medicaldialogues.in)per also say the HbA1c advantage was still there at 32 weeks, after a second phase that included clinician support. (abbott.mediaroom.com) ### Why would CGM help if the medication stayed similar? Because glucose data changes behavior. A finger-prick test gives you a snapshot. A re(thelancet.com)ther the basal dose looks too weak or too strong. For people self-managing type 2 diabetes, that turns abstract advice into immediate feedback. The improvement in FreeDM2 was described as largely participant-led, which is a big part of why the result stands out. (abbott.mediaroom.com) ### Does this mean everyone with type 2 diabetes should get one? Not a(abbott.mediaroom.com)tion for people on no insulin, or for people with very different treatment plans. And cost-effectiveness still matters — especially if health systems are deciding who gets reimbursed. (thelancet.com) ### Why does the publication matter beyond one trial? Because this is the kind of evidence that can move guidelines, coverage, and routine care. An editorial published alongside the study argued that CGM use in type 2 dia(abbott.mediaroom.com)kes the “basal insulin isn’t enough to justify CGM” position harder to defend. (thelancet.com) ### So what’s the bottom line? The practical takeaway is simple: better information helped this group manage diabetes better. Not because CGM is magic, but because seeing glucose rise and fall in real time gives people something finger sticks usually(thelancet.com)ehind it. (medicaldialogues.in)
